| Product Name | Application | Status | Modality |
|---|---|---|---|
| BB-101 | DFU | Phase II | Topical Administration |
| 產品名稱: | BB-101 |
|---|---|
| 有效成分： | BB-101 |
| 適應症： | 雄性禿 |
| 研發階段： | 臨床二期前 |
| 產品類型： | 外用滴劑 |
Read more
Diabetic foot ulcers (DFUs) are common and severe complications of diabetes, often resulting from poor blood circulation, fibroblast dysfunction, neuropathy, and impaired angiogenesis, leading to chronic and hard-to-heal wounds. According to the World Health Organization, DFUs that do not heal within 8 weeks may lead to complications, including amputation. Under standard treatment, only 20-40% of ulcers heal within 12 weeks. Insufficient angiogenesis is one of the common causes of failed healing, highlighting the urgent need for novel therapeutic approaches.
BB-101 is a patented protein with unique therapeutic properties, jointly developed by our company in collaboration with the Institute of Biochemistry and Molecular Biology at National Cheng Kung University. It has demonstrated the ability to promote cell migration and angiogenesis, leveraging its biological properties to develop a treatment for diabetic foot wounds.
In the Phase I clinical trial, BB-101 exhibited a high level of safety. It is currently undergoing Phase II clinical trials, with the aim of providing patients with a more effective and safer therapy.
| Age Ancla | BB-101 | 雄性禿 | 臨床一期 | 微針貼片 |
| 產品名稱: | Age Ancla |
|---|---|
| 有效成分： | BB-101 |
| 適應症： | 雄性禿 |
| 研發階段： | 臨床一期 |
| 產品類型： | 微針貼片 |
更多關於Age Ancla
糖尿病足潰瘍（DFUs）是糖尿病常見且嚴重的併發症，通常由於血液循環不良、成纖維細胞功能障礙、神經病變及血管新生受損等因素導致慢性且難以癒合的傷口。跟據世界衛生組織，若 DFUs 在 8 週內無法癒合，可能會引發併發症，甚至需要截肢，而在標準治療下，僅有 20-40% 的潰瘍能在 12 週內癒合。血管新生不足是癒合失敗的常見原因之一，凸顯了開發新型治療方法的必要性。
BB-101為寶血與國立成功大學生物化學暨分子生物學研究所合作，共同研發之特殊功效專利蛋白，具有促進細胞移行和血管新生的能力，利用其生物特性，開發治療糖尿病足傷口的藥物。
在第一期的臨床試驗中，BB-101展現了高度的安全性，目前正積極進行第二期臨床試驗，期望為患者提供更有效且安全的療法。